Delcath doses first patient in breast cancer trial of Hepzato

July 9, 2026 8:00 AM

Delcath Systems, Inc. (Nasdaq: DCTH) announced that the first patient has been dosed in its global Phase 2 clinical trial ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found